Dicerna Pharmaceuticals Stock Cash And Equivalents
Dicerna Pharmaceuticals fundamentals help investors to digest information that contributes to Dicerna Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Dicerna Stock. The fundamental analysis module provides a way to measure Dicerna Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Dicerna Pharmaceuticals stock.
Dicerna |
Dicerna Pharmaceuticals Company Cash And Equivalents Analysis
Dicerna Pharmaceuticals' Cash or Cash Equivalents are the most liquid of all assets found on the company's balance sheet. It is used in calculating many of the firm's liquidity ratios and is a good indicator of the overall financial health of a company. Companies with a lot of cash are usually attractive takeover targets. Cash Equivalents are balance sheet items that are typically reported using currency printed on notes.
Current Dicerna Pharmaceuticals Cash And Equivalents | 565.51 M |
Most of Dicerna Pharmaceuticals' fundamental indicators, such as Cash And Equivalents, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Dicerna Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Cash equivalents represent current assets that are easily convertible to cash such as short term bonds, savings account, money market funds, or certificate of deposits (CDs). One of the important consideration companies make when classifying assets as cash equivalent is that investments they report on their balance sheets under current assets should have almost no risk of change in value over the next few months (usually three months).
CompetitionIn accordance with the recently published financial statements, Dicerna Pharmaceuticals has 565.51 M in Cash And Equivalents. This is 31.11% lower than that of the Healthcare sector and 26.48% higher than that of the Biotechnology industry. The cash and equivalents for all United States stocks is 79.07% higher than that of the company.
Dicerna Cash And Equivalents Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Dicerna Pharmaceuticals' direct or indirect competition against its Cash And Equivalents to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Dicerna Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Dicerna Pharmaceuticals by comparing valuation metrics of similar companies.Dicerna Pharmaceuticals is currently under evaluation in cash and equivalents category among its peers.
Dicerna Fundamentals
| Return On Equity | -95.22 | |||
| Return On Asset | -10.43 | |||
| Profit Margin | (64.53) % | |||
| Operating Margin | (62.88) % | |||
| Current Valuation | 2.48 B | |||
| Shares Outstanding | 77.91 M | |||
| Shares Owned By Insiders | 7.43 % | |||
| Shares Owned By Institutions | 88.54 % | |||
| Number Of Shares Shorted | 4.77 M | |||
| Price To Earning | (1.58) X | |||
| Price To Book | 27.64 X | |||
| Price To Sales | 15.44 X | |||
| Revenue | 192.85 M | |||
| Gross Profit | (41.08 M) | |||
| EBITDA | (116.73 M) | |||
| Net Income | (124.44 M) | |||
| Cash And Equivalents | 565.51 M | |||
| Cash Per Share | 7.26 X | |||
| Total Debt | 64.42 M | |||
| Debt To Equity | 0.60 % | |||
| Current Ratio | 2.46 X | |||
| Book Value Per Share | 1.38 X | |||
| Cash Flow From Operations | 21.05 M | |||
| Short Ratio | 0.84 X | |||
| Earnings Per Share | (1.63) X | |||
| Number Of Employees | 302 | |||
| Beta | 0.79 | |||
| Market Capitalization | 2.98 B | |||
| Total Asset | 62.95 M | |||
| Retained Earnings | (539.14 M) | |||
| Working Capital | 49.56 M | |||
| Current Asset | 59.38 M | |||
| Current Liabilities | 9.82 M | |||
| Z Score | 16.1 |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Other Consideration for investing in Dicerna Stock
If you are still planning to invest in Dicerna Pharmaceuticals check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Dicerna Pharmaceuticals' history and understand the potential risks before investing.
| Sectors List of equity sectors categorizing publicly traded companies based on their primary business activities | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Bollinger Bands Use Bollinger Bands indicator to analyze target price for a given investing horizon | |
| Portfolio Diagnostics Use generated alerts and portfolio events aggregator to diagnose current holdings |